Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Ipilimumab × Endocrine × Clear all

Phase

Status

Active not recruiting 7 Terminated 1 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 104 Genitourinary 44 Thoracic 42 Gastrointestinal 35 Head & Neck 16 Other solid neoplasm 14 Tumor-Agnostic 13 Gynecologic 12 Sarcoma 11 CNS 11 Breast 11 Lymphoid 9 Other hematologic neoplasm 6 Myeloid 6 Plasma cell 2 Endocrine 1

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Everolimus 28 Octreotide 13 Cisplatin 12 Sunitinib 10 Etoposide 9 Doxorubicin 8 pembrolizumab 7 pasireotide 7 lutetium Lu 177 dotatate 7 lanreotide 7 Temozolomide 7 3-Iodobenzylguanidine 7 gallium Ga 68 dotatate 6 Positron Emission Tomography Computed Tomography 6 Magnetic Resonance Spectroscopy 6 Bevacizumab 6 pazopanib 5 Surgical Procedures, Operative 5 Radiotherapy 5 Paclitaxel 5 Irinotecan 5 Fulvestrant 5 surufatinib 4 lenvatinib 4 avelumab 4 Sorafenib 4 Radiosurgery 4 Mitotane 4 Iodine-131 4 Gefitinib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03591731 2025-04-01

NIPINEC

Intergroupe Francophone de Cancerologie Thoracique

Phase 2 Completed

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡